Published as part of the 30 Years SYNLETT – Pearl Anniversary Issue
Abstract
A four-step synthesis of the FDA-approved anticancer agent gefitinib was developed
starting from 2,4-dichloro-6,7-dimethoxyquinazoline. Reaction temperatures were highly
practical (0–55 °C), and chromatographic purifications were avoided. The ionic liquid
trimethylammonium heptachlorodialuminate was used to monodemethylate the dimethoxyquinazoline
core. In the final step, a selective dehalogenation was employed to provide gefitinib
in 14% overall yield on a gram scale.
Key words
ionic liquids - demethylation - nucleophilic aromatic substitution - dehalogenation
- gefitinib - medicinal chemistry